Objective To perform a meta-analysis examining the effi cacy of phytoestrogens for the relief of menopausal symptoms.
INTRODUCTION
Menopause is characterized by a decrease in estrogen, which triggers the uncomfortable symptoms of hot fl ushes, night sweats, sleep disturbances, and vaginal dryness. Among these menopausal symptoms, hot fl ushes are reported by many women to be the most bothersome 1 . The symptoms of menopause as a result of decreasing estrogen levels can signifi cantly affect quality of life 2 . While hormone replacement therapy (HRT) effectively reduces vasomotor symptoms associated with the decrease of estrogen levels during menopause, results of the Women ' s Health Initiative (WHI) trial indicated that the benefi ts of HRT did not outweigh the risks 3 , as estrogen alone would increase risks of stroke and venous thromboembolism (VTE), and together with progestin could incur additional risks of causing breast cancer and heart attack. As a result, the role of HRT has been limited to treat postmenopausal symptoms at minimal dose and duration, and more effi cacious and better tolerated alternatives to decrease menopausal symptoms are still being sought 4 -6 .
Phytoestrogens are plant compounds with estrogen-like properties 7 . The two major classes of phytoestrogens are isofl avones and lignans; soybeans are rich in isofl avones, and lignans are found in fl axseed, whole grains, legumes, fruits, and vegetables 8 . The chemical structures of isofl avones and lignans are similar to that of estradiol, and these compounds appear to exert an estrogenic or antiestrogenic effect depending on the circulating estrogen level (i.e. they exert an antiestrogenic effect when the circulating estrogen level is high, but when the estrogen level is low, their effect becomes more estrogenic) 7 . There is much interest in the use of phytoestrogens to treat menopausal symptoms, in part because vasomotor symptoms are much less frequently experienced by Asian women than by women in America or Europe 9 , and because the Asian diet being rich in phytoestrogens may be a contributing factor 10 . Though there has been a large amount of research devoted to determine whether phytoestrogens are well tolerated and effective for the treatment of menopausal symptoms, study results have been inconclusive and no consensus on their utility has been reached 7, 11, 12 . Confl icting data may be due to multiple factors including variations in studies ' inclusion criteria, types and dosages of consumed phytoestrogens, the lack of appropriate study controls, control for the consumption of phytoestrogens from other sources, and differences in the outcome measures used 7, 11, 12 . There is also a need for more well-funded studies on potential longterm adverse effects of phytoestrogens such as heart diseases, breast cancer, VTE and stroke.
The purpose of this study was to perform a meta-analysis of high-quality, randomized, controlled trials (RCTs), to evaluate the effectiveness and short-term side-effects of phytoestrogens in alleviating menopausal symptoms and improving quality of life.
METHODS

Literature search strategy
Medline, Cochrane, EMBASE and Google Scholar databases were searched until September 30, 2013 using combinations of the following key words: vasomotor symptoms, menopausal symptoms, phytoestrogens, isofl avones, coumestrol, soy, red clover. Reference lists of relevant studies were handsearched.
Inclusion criteria for this meta-analysis were (1) RCT, (2) subjects were perimenopausal or postmenopausal women experiencing menopausal symptoms, (3) the intervention was a phytoestrogen (e.g. isofl avone, genistein, soy extract), and (4) the intervention was in oral form. Studies were excluded from the analysis if (1) there was no placebo control group, (2) there was only an active control group (e.g. hormone replacement therapy), and (3) numerical outcome data were not provided.
Study selection, data extraction and quality assessment
Studies were identifi ed via the search strategy by two independent reviewers. When there was uncertainty regarding eligibility, a third reviewer would be consulted. The following information/data were extracted from studies that met the inclusion criteria: the name of the fi rst author, year of publication, study design, participants ' age and gender, diagnosis, number of participants in each treatment group, treatment, length of follow-up, function and quality-of-life outcomes, and side-effects. The Delphi list was used to assess the quality of the included studies 13 .
Outcome measures
Outcome measures included changes in Kupperman index (KI) 14 , changes in daily hot fl ush frequency, and the likelihood of side-effects. Briefl y, the Kupperman index covers 11 menopausal symptoms including hot fl ushes (vasomotor), paresthesia, insomnia, nervousness, melancholia, vertigo, weakness, arthralgia or myalgia, headache, palpitations, and formication. Each symptom is rated on a scale from 0 to 3 for having no, slight, moderate or severe complaints, respectively, with the highest possible total score being 51.
Statistical analysis
The mean differences between treatment groups in changes in KI and daily hot fl ush frequency were calculated to evaluate the effi cacy of phytoestrogens, and the odds ratios (ORs) of side-effects occurring were calculated to evaluate the safety of phytoestrogens. A χ 2 -based test of homogeneity was performed using Cochran ' s Q statistic and I 2 . The percentage of the total variability in effect estimates among trials that are due to heterogeneity rather than chance is expressed by I 2 . Randomeffects models of analysis were used if heterogeneity was detected ( Q statistic with p Ͻ 0.1 or I 2 Ͼ 50%). The pooled estimates of mean differences in KI change, mean differences in change of daily hot fl ush frequency, and the pooled estimates of ORs of side-effects were calculated. Sensitivity analysis was performed based on the leave-one-out approach. The onesided Egger's test and Funnel plots were performed to evaluate publication bias. The homogeneity test, pooled estimates, and sensitivity analysis were performed by using Comprehensive Meta-Analysis, version 2.0 (Biostat, Englewood, NJ, USA). A value of p Ͻ 0.05 indicates statistical signifi cance.
RESULTS
Literature search and study characteristics
A fl ow diagram of study selection is shown in Figure 1 . A total of 543 potentially relevant articles were initially
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Chen, Lin and Liu identifi ed and screened, and 488 of them were subsequently excluded. Of the 55 full-text articles reviewed, 40 were excluded and ultimately 15 studies 11,15 -28 were included in the meta-analysis. The characteristics and outcomes of the 15 studies are summarized in Tables 1 and 2 .
The mean age of the subjects ranged from 49 to 58.3 and 48 to 60.1 years, in the placebo and phytoestrogen groups, respectively. The number of participants in the studies ranged from 30 to 252, and the intervention periods ranged from 3 to 12 months. Seven studies reported the KI at baseline and after intervention [17] [18] [19] [20] [23] [24] [25] , while ten studies reported hot fl ush frequency at baseline and after intervention, or change from baseline 11,15,16,19,21 -23,26 -28 . As expected, there was no signifi cant difference in baseline KI and hot fl ush frequency between treatment and placebo groups, since the participants were randomly allocated. Only fi ve studies reported the number of side-effects 19, 21, 23, 26, 28 .
Change in Kupperman index
Of the seven studies that reported KI data 17 -20,23 -25 , three reported a signifi cant reduction of KI in the phytoestrogen group when compared with the placebo group 17, 20, 25 , while the other four 18, 19, 23, 24 reported no difference between the groups. Meta-analysis of the seven studies indicated no signifi cant treatment effect of phytoestrogen when compared to placebo (pooled mean difference ϭ 6.4, p ϭ 0.110, Figure 2a ). The pooled estimate remained positive and non-signifi cant after sensitivity analysis based on the leave-one-out approach was made, indicating there was no infl uence of individual studies on the pooled estimate ( Figure 2b ). 
Daily hot fl ush frequency
Of the ten studies that reported hot fl ush frequency data 11,15,16,19,21 -23,26 -28 , four reported a signifi cant reduction of hot fl ush frequency in the phytoestrogen group when compared to the placebo group 15, 19, 21, 23 , while the other six 11,16,22,26 -28 reported no signifi cant difference between the groups. Meta-analysis of the ten studies indicated that the phytoestrogen group had a signifi cant reduction in hot fl ush frequency when compared with the placebo (pooled mean difference ϭ 0.89, p Ͻ 0.005, Figure 3a) . The pooled estimate remained positive and signifi cant after sensitivity analysis based on the leave-one-out approach was made, indicating there was no infl uence of individual studies on the pooled estimate ( Figure 3b ).
Likelihood of side-effects
Four 19,21,23,26 of the fi ve studies that reported the number of side-effects showed no signifi cant difference in the numbers of side-effects between groups. The study by Van Patten and colleagues 28 reported that the subjects in phytoestrogen group were less likely to experience side-effects than those in the placebo group (OR ϭ 0.31, p ϭ 0.003). Meta-analysis of the fi ve studies showed no signifi cant difference in side-effects between the two groups ( p ϭ 0.175, Figure 4a ). With the exception of the study by Tice and colleagues 26 , when each of the other studies was removed in turn, the pooled ORs remained Ͻ 1 and non-signifi cant. When the study by Tice and colleagues 26 was removed, the pooled OR reached statistical signifi cance ( p ϭ 0.034) (Figure 4b ).
Evaluation of publication bias
Egger's test for KI (seven studies) 17 -20,23 -25 showed the estimated intercept to be Ϫ 10.01, with a one-tailed p value ϭ 0.043, which indicated a signifi cant asymmetry in the funnel plot (Figure 5a ). Egger's test for hot fl ush frequency (ten studies) 11,15,16,19,21 -23,26 -28 showed the estimated intercept to be 2.99, with a one-tailed p value ϭ 0.036, which indicated a signifi cant asymmetry in the funnel plot (Figure 5b ). Egger's test for side-effects (fi ve studies) 19, 21, 23, 26, 28 showed the estimated intercept to be Ϫ 1.92 with one-tailed p value of 0.185 (non-signifi cant) which indicated no signifi cant asymmetry in the funnel plot (Figure 5c ).
Quality assessment
Results of the analysis of quality assessment are shown in Figure 6 .
DISCUSSION
Phytoestrogens are commonly used for the relief of menopausal symptoms, but studies have provided confl icting results of their effi cacy. The results of this meta-analysis including 
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15 high-quality RCTs showed that, although the use of phytoestrogens did not result in a change of KI when compared to the use of placebo, they did signifi cantly reduce the frequency of hot fl ushes as compared with the placebo. In addition, there was no difference in the occurrence of side-effects between patients who received phytoestrogens and those who received placebo. There is a large body of research devoted to determine the effi cacy of phytoestrogens in treating menopausal symptoms, and a search of PubMed using the terms " phytoestrogen, menopause " produces well over 800 results. However, results of many studies are confl icting and there is still a lack of consensus on their effi cacy 7, 12, 30 . Some of the reasons for these confl icting data include variations in the study design, variable types and dosage of consumed phytoestrogen, lack of appropriate study controls, a lack of controls for the consumption of phytoestrogens from other sources, and differences in the outcome measures used 7, 11, 12 . Although many studies have shown phytoestrogens can reduce the vasomotor symptoms of menopause 15,17,19 -23,25,27 , many others have not 11, 16, 18, 22, 24, 26, 28 . Two recent reviews and meta-analyses have found little conclusive evidence on the effectiveness of phytoestrogens for treating vasomotor symptoms associated with menopause 12, 30 . In 2009, Jacobs and colleagues 30 performed a systematic review of the literature including 17 randomized and placebo-controlled trials that investigated soy isofl avones and reported that the interventions and outcome measures in those studies were so highly heterogeneous that a meta-analysis could not be made. Their systematic review decided that there were qualitative defi ciencies in the studies and a consistent reduction in hot fl ushes was not present. A more recent (2013) Cochrane review of the literature of phytoestrogens for menopausal vasomotor symptoms had included 43 RCTs with a total of 4364 participants, but found that very few studies actually provided data suitable for metaanalysis, so they too were unable to reach a conclusion on the effi cacy of phytoestrogens 12 .
A recent review of fi ve meta-analyses and one review investigating the impact of phytoestrogens on menopausal symptoms concluded that isofl avones did not relieve menopausal vasomotor symptoms 31 . Our meta-analysis indicated that phytoestrogens did not result in a signifi cant decrease of the KI, but did reduce the frequency of hot fl ushes compared with placebo. Hot fl ushes occur in up to 74% of postmenopausal women and can have a negative impact on quality of life; they can still be experienced by some women in their seventies 32 . The Kupperman index represents more comprehensive grouping of 11 menopausal symptoms which include not only hot fl ushes (vasomotor), but also paresthesia, insomnia, nervousness, melancholia, vertigo, weakness, arthralgia/myalgia, headache, palpitations, and formication. The lack of significant reduction in KI found in our analysis does cast doubt on the utility of phytoestrogens in alleviating menopausal symptoms other than hot fl ushes. It is also important to note the high heterogeneity among the included studies in this metaanalysis. There were differences in participant numbers, ages, doses used and outcomes which were recorded. Only seven studies reported KI data, while fi ve studies recorded sideeffects and ten studies reported frequency of hot fl ushes. This wide heterogeneity makes interpretation of data challenging.
A review by Bolanos and colleagues 33 in 2010 specifi cally examined soy isofl avones versus placebo in the treatment of menopausal vasomotor symptoms and found that, although there was a tendency to favor the effectiveness of soy isofl avones, the heterogeneity of studies was high. In the aforementioned Cochrane review 12 , three placebo-controlled studies reported a signifi cant reduction in the frequency of hot fl ushes from the use of soy extracts as compared with placebo (21%, 43% and 38% reduction, respectively). Few studies have compared the effect of phytoestrogens or soy products with HRT. In a double-blind, RCT of low-dose hormone therapy, Carmignani and colleagues 34 treated symptomatic postmenopausal women with either a regimen of 1 mg estradiol and 0.5 mg norethisterone acetate, daily dietary soy supplementation containing 90 mg of isofl avone, or placebo for 16 weeks and reported that patients who received soy supplementation and hormone therapy had a 49.8% and 45.6% reduction in hot fl ushes, respectively. Similarly, Crisafulli and colleagues 35 evaluated the effects of the phytoestrogen genistein (an isofl avone), estrogen -progesterone HRT, and placebo on hot fl ushes in postmenopausal women and reported a 22% daily reduction in hot fl ushes in the genistein group after 12 weeks of treatment when compared with placebo, and a 53% reduction after 12 weeks when compared with placebo in the HRT group. Interestingly, decreased estrogen levels at menopause were accompanied by a signifi cant decrease in BRCA1 and BRCA2 mRNA levels in placebo-treated women, but this was reversed in genistein-treated women 36 . Bone mineral density for femoral neck and lumbar spine was higher in genisteintreated women compared to placebo 36 , and genistein did not signifi cantly increase the risk of hypothyroidism compared to placebo 37 . Furthermore, a randomized trial of 224 postmenopausal women showed no signifi cant difference in endometrial thickness or rates of endometrial hyperplasia or cancer in women receiving an isofl avone soy protein supplement compared to placebo-treated women 38 .
Lignans have not been as extensively studied as isofl avones, but the currently available data suggest that their effectiveness for reducing the vasomotor symptoms of menopause was no better than placebo. A double-blind, placebo-controlled RCT performed in 2010 by Simbalista and colleagues 39 studied two groups of postmenopausal women with one group consuming two slices of bread containing 25 g of fl axseed (46 mg lignans) and the other group consuming wheat bran ( Ͻ 1 mg lignans; control group) daily for 12 weeks, and reported similar reduction in hot fl ush frequency and KI in both groups. Likewise, Pruthi and colleagues 40 randomized 188 postmenopausal women to consume a fl axseed bar (410 mg of lignan) or a placebo bar daily for 6 weeks, and found that in both groups there were approximately one-third of women reported a 50% reduction in hot fl ushes.
The majority of studies examining the roles of phytoestrogens in alleviating menopausal symptoms do not investigate their potential side-effects; of the 15 RCTs included in this meta-analysis, only fi ve reported side-effect data. However, these studies were consistent with the results of this analysis, because they also found side-effects of phytoestrogen consumption to be no different from that with placebo. Most studies indicate that phytoestrogens are well tolerated without serious side-effects 12,31,41 . Our side-effect data were consistent with a recent meta-analysis which reviewed 174 RCTs and reported that phytoestrogens had a safe side-effect profi le 42 . The rates of hormonal side-effects such as endometrial hyperplasia, endometrial cancer and breast cancer were no higher among phytoestrogen-treated women than placebo-treated women 42 . Though data are not conclusive, consumption of isofl avones by menopausal women 7 may have a positive impact on vaginal atrophy, sleep disturbances, bone mineral density, and cognition. In addition, phytoestrogens do not seem to result in breast cancer or endometrial hyperplasia 7 , and may actually exert a positive effect on lipid profi le 23 .
There are limitations of this study that should be considered. As with other similar meta-analyses, this meta-analysis is limited by the heterogeneity of the included studies. There was a lack of standardization in dosage used, and the compliance data were not available. In addition, isofl avones were the phytoestrogens used in the majority of the studies, and few studies with other phytoestrogens were included; outcomes with other phytoestrogens were therefore not examined. Furthermore, publication biases detected in the Egger ' s tests for KI as well as frequency of hot fl ushes might be due to the small number of studies included in this analysis. Despite these shortcomings, the similarities in inclusion criteria and outcome measures among the included studies aided the comparison and analysis.
In conclusion, results of this meta-analysis indicate that, while phytoestrogens did not bring a decrease in KI compared to placebo, their use was associated with a reduction in the hot fl ush frequency and their side-effects were no more common than those with placebo. While the available data do not support the recommendation of phytoestrogens for relief of all menopausal symptoms, some patients may benefi t from their use in reducing hot fl ushes as these compounds also seem to be well tolerated. As the current data are inconclusive, further study of phytoestrogens for the relief of menopausal symptoms and their potential long-term adverse effects is warranted.
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